Umair Gauhar, MD
Pulmonary Disease · Louisville, KYNPI 1063626653
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (57.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Intuitive Surgical at 58.4% of the total. Reporting peaked in 2023 at $3,060 and has fallen 87.7% since, to $378 in 2025.
Across 51 payments — averaging $152.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Pulmonx Corporation$2K
- Johnson & Johnson$547
- Galvanize Therapeutics, Inc$214
- Novartis$51
- Boehringer Ingelheim$44
- plus $199 from 11 others
What the payments were for
- Consulting fees$2003%
- Travel & lodging$1,61721%
- Food & beverage$1,47019%
- Education$4,50058%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $4,544 |
| Pulmonx Corporation | 18 | $2,187 |
| Johnson & Johnson(2 entities) | 11 | $547 |
| Galvanize Therapeutics, Inc | 1 | $214 |
| Novartis | 3 | $51 |
| Boehringer Ingelheim | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Medical Device Business Services, Inc. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $23 |
| Ambu Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Amgen | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,787 in reported general payments places this provider in the 65th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,159 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,467 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $328 |
| Azithromycin | 14 | $66 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.